Report
EUR 165.22 For Business Accounts Only

Moody's affirms Yamana's Baa3 rating following announced acquisition by Pan American; outlook stable

Moody's Investors Service ("Moody's")  has affirmed Yamana Gold, Inc's ("Yamana") Baa3 senior unsecured ratings following its announcement that Yamana entered into an arrangement agreement with Agnico Eagle Mines Limited ("Agnico") and Pan American Silver Corp. ("Pan American").  The outlook remains...
Underlying
Yamana Gold Inc.

Yamana Gold is engaged in the exploration, development, extraction, processing and reclamation of gold and other precious metals mining throughout the Americas including Brazil, Argentina, Chile, Mexico and Colombia. As of Dec 31 2011, total proven reserves for gold, silver, cooper, zinc and molybdenum was 618,709,000 tonnes, 27,316,000 tonnes, 387,660,000 tonnes, 5,004,000 tonnes and 32,000,000 tonnes, respectively.

Provider
Moody's Investors Service
Moody's Investors Service

Moody's Investors Service is a leading provider of credit ratings, research, and risk analysis. Moody's commitment and expertise contributes to transparent and integrated financial markets, protecting the integrity of credit. Our ratings and analysis track debt covering more than:

  • 130 countries
    11,000 corporate issuers
    21,000 public finance issuers
    76,000 structured finance obligations



Credit ratings and research help investors analyze the credit risks associated with fixed-income securities. Such independent credit ratings and research also contribute to efficiencies in fixed-income markets and other obligations, such as insurance policies and derivative transactions, by providing credible and independent assessments of credit risk.



Moody’s default studies validate our predictive ratings. Our published research and investor briefings draw thousands of attendees each year and keep investors current with the rationale underlying our credit opinions. 

Other Reports on these Companies
Other Reports from Moody's Investors Service

ResearchPool Subscriptions

Get the most out of your insights

Get in touch